Soluble Urokinase Plasminogen Activator Receptor (suPAR) in Late-onset Neonatal Sepsis
NCT ID: NCT01294865
Last Updated: 2011-02-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
120 participants
OBSERVATIONAL
2010-01-31
2012-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Plasma Soluble Urokinase Plasminogen Activator Receptor and Behçet's Disease .
NCT04105439
SuPAR in Adult Patients With Covid-19
NCT04590794
The Potential Role of sRAGE, KL-6, and SP-D as Prognostic Factors in Children With COVID-19
NCT05619640
Sepsis-Associated Purpura Fulminans International Registry - Europe
NCT02238795
Annexin A1 Levels in SARS-CoV-2 Infection
NCT04948229
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
septic
Infants having clinical suspected late-onset neonatal sepsis enrolled in the study. Blood samples for suPAR were obtained before initiating antibiotic treatment and at the end of the treatment with other laboratory tests.
No interventions assigned to this group
non-septic
Infants without any clinical or hematological septic signs. Blood samples will be taken only once.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
4 Days
1 Month
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ankara University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ankara University
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Saadet Arsan, Professor
Role: STUDY_DIRECTOR
Ankara University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ankara University Faculty of Medicine, Department of Pediatrics
Ankara, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Okulu E, Arsan S, Akin IM, Ates C, Alan S, Kilic A, Atasay B. Serum Levels of Soluble Urokinase Plasminogen Activator Receptor in Infants with Late-onset Sepsis. J Clin Lab Anal. 2015 Sep;29(5):347-52. doi: 10.1002/jcla.21777. Epub 2014 Jul 10.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Ankara University
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
Ankara University-02
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.